Affini-T Therapeutics

Next week, our CEO, Jak Knowles, is presenting at @jpmorgan's #JPM2025. Connect with us in #SanFrancisco to learn more about our latest advancements in #cancer research and #Tcell therapies targeting #tp53 and #KRAS, bit.ly/4h8LHEs. #immunotherapies #solidtumor #JPM25

We’re ready to leap into 2025 and are grateful for the continued support of the incredible team at @LeapsByBayer ! #Biotech #Cancer #CellTherapy #TCells #SolidTumors

Affini-T’s Ankit Gupta, Senior Director, Head of Gene Editing, will present “AFNT-212: A Non-Viral Gene-Edited TCR-T Cell Therapy” to industry and academic leaders at the 5th Genome Editing Therapeutics Summit in #Boston today. Learn more about it here: bit.ly/3BflF2Q. #CRISPR #GeneEditing #DrugDevelopment #TCells

Today, Kathy Bergsteinsson, our CFO, will be at @Piper_Sandler's 36th Annual Healthcare Conference in #NewYork where she’ll present a corporate update and participate in 1:1 meetings. Connect with her to learn more about our work to develop #KRAS-targeting precision #immunotherapies for patients with #solidtumors.

We are heading across the pond for @Jefferies London Healthcare Conference. Our CEO, Jak Knowles, CFO, Kathy Bergsteinsson, and CSO, Loïc Vincent, will share our latest advancements in #cancer research and #Tcell therapies targeting #tp53 and #KRAS mutations during 1X1 meetings. Connect with them to discuss how we’re working to advance precision #immunotherapies to bring potentially curative treatments to patients facing some of the most difficult-to-treat #solidtumor cancers. #JefferiesHealthcare

We look forward to presenting at the @sitcancer (SITC) 39th Annual Meeting, where we will showcase a Trial-in-Progress poster and three posters with preclinical data from our #oncogenicdriver programs. And for the first time, we will also unveil data for bispecific T cell engagers targeting #KRAS and #TP53. For more details on our poster presentations, please visit: bit.ly/3YR0cGq. #SITC24 #Immunotherapy #SolidTumors

We’re live in #Anaheim at the @ASHIHQ 50th Annual Meeting! Stop by and meet with our team during today’s poster session. Details: Poster #203, Platinum Ballroom, “Integrating US Census Demographic Data with HLA Frequencies to Accelerate Targeted Cell Therapy Patient Enrollment”, bit.ly/3NBjzwM. #ASHI2024 #Tcell therapies #solidtumors #HLATyping

Tuning in to the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum? Connect with our CEO, Jak Knowles, and CFO, Kathy Bergsteinsson, to learn more about our work to target the most frequent #oncogenicdriver mutations in #solidtumors including #KRAS, #TP53 and #PIK3CA. #biotech

We are excited to meet with industry leaders, peers, and investors at three events today. If you’re attending any of these conferences and would like to learn more about our work advancing #TCRT #precisionimmunotherapies for patients with #solidtumors, please reach out to us. We look forward to connecting with you! @rbccm | @ChardanCM | @GoldmanSachs #ChardanGMConf #CellTherapy

Gary Shapiro, our VP, Discovery Biology, is presenting today at the 22nd Annual @BostonDOT. Learn more about his presentation here: bit.ly/3ZIMd6s. #BostonDOT24 #drugdiscovery #solidtumors

Today, our CEO, Jak Knowles, and CFO, Kathy Bergsteinsson, will be at the @BankofAmerica Healthcare Trailblazers Private Company Conference in #Boston. Connect with them to learn more about our recent progress and pipeline of #precisionimmunotherapies for #solidtumors. #TCRT

Attending the 9th Annual CAR-TCR Summit in Boston today and tomorrow? You’ll have several opportunities to listen and meet with team members at three presentations and a panel. For more details and a full schedule, head to the event site: bit.ly/4dzmL7y #CARTCRSummit #solidtumors #Tcelltherapies #KRAS #tp53

Kathy Bergsteinsson, our CFO, will be at Cantor’s 2024 Global Healthcare Conference in #NewYork today where she’ll participate in 1:1 meetings. Connect with her to learn more about our work to develop #KRAS-targeting precision #immunotherapies for patients with #solidtumors. #CantorHCC

Later today, Affini-T’s Ankit Gupta, Senior Director, Head of Gene Editing, will join @scribetx's Kai-Yuan Chen and co-lead a workshop discussing gene-editing off-target analysis methods within regulatory context at the 2nd CRISPR-Based Therapy Analytical Development Summit in #Boston. Learn more about it here: bit.ly/4deNJAd. #DrugDevelopment #CRISPR #GeneEditing #Biotech

Tomorrow, CEO Jak Knowles and CFO Kathy Bergsteinsson will participate in 1:1 meetings at the @MorganStanley 22nd Annual Global Healthcare Conference in #NewYorkCity. Engage with them and discover more about our latest advancements in #cancer research and #Tcell therapies targeting #KRAS and #tp53 mutations. #immunotherapies #solidtumors

Attending @WellsFargo's Healthcare Conference in #Boston tomorrow? Connect with our CSO, Loïc Vincent, and learn more about our work developing specific TCR-based #immunotherapies for patients with #solidtumors using two complementary therapeutic modalities: autologous #TCR-T #CellTherapies and bispecific #TCell Engagers.

Today, Gary Shapiro, Affini-T’s VP, Discovery Biology, is at @UCLA sharing his deep #biotech and #pharma industry experience and perspective with students and post-docs in a seminar highlighting the differences, unique rewards and challenges in career paths in Academia and Industry.

Our CEO, Jak Knowles, and CFO, Kathy Bergsteinsson, will be at the @Stifel Biotech Executive Summer Summit in Newport, RI this week. Connect with us to learn more about our work advancing durable #TCRT #precisionimmunotherapies for #solidtumor patients.